MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico

• Główni autorzy: Aurelio Cruz-Valdez (Autor), Gabriel Valdez-Zapata (Autor), Sanjay S. Patel (Autor), Flavia V. Castelli (Autor), Marcia G. Garcia (Autor), Wim T. Jansen (Autor), Ashwani Kumar Arora (Autor), Esther Heijnen (Autor)
• Format: Książka
• Wydane: Taylor & Francis Group, 2018-02-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

The poor immune response elicited by trivalent influenza vaccines (TIVs) in children can be enhanced by the addition of adjuvants. This observer-blind, randomized Phase III trial assessed the immunogenicity and safety of the MF59-adjuvanted trivalent influenza vaccine FLUAD® (aTIV) and a non-adjuvan...